Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM + NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3) Meeting Abstract
| Authors: | Chandana, S. R.; Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R. A.; De La Fouchardiere, C.; Dean, A. P.; Kiss, I.; Lee, W. J.; Goetze, T.; Van Cutsem, E.; Paulson, A. S.; Bekaii-Saab, T. S.; Pant, S.; Hubner, R.; Xiao, Z.; Li, J.; Benzaghou, F.; O'Reilly, E. M. |
| Abstract Title: | Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM + NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3) |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Keywords: | 613-135-2370-7650-2700; 3282-415-5268-2723-6700; 283-237-267-6887 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500450 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.687 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 687 -- Source: Wos |
